Novartis raised its profit outlook even as a drug trial failure led to a $1.9 billion charge
Novartis AG raised its profit outlook for the year as growth from newer medicines increasingly offset the hit from generic competition to former blockbuster Entresto.
3 across the spectrum. Choose a side on the bar to jump to it.
National story. 3 articles from 3 sources. Updated 7d ago.
How each side is putting it
Left
2 sourcesCenter
0 sourcesNo Center coverage yet.
A blind spot on this side of the story.